PDCD1 and melanoma: Moreover, the presence of liver metastasis is associated with reduced response to anti-PD-1 checkpoint blockade (Pembrolizumab) in melanoma or non-small-cell lung cancer (NSCLC) patients compared to patients without liver metastasis [78].